



# Editorial

## Vitamin D: Way More Important in Critical Care Than We May Have Recognized

**C**ritical care nurses are familiar with the role of Vitamin D in maintaining skeletal integrity, but may not be aware of its importance in numerous other physiologic activities relevant to our patient populations. Much of the attention to vitamin D has come to light indirectly, as the ill effects of vitamin D deficiency (VDD) related to cardiovascular disease (CVD), immunity, infection, cognition, and mortality were uncovered.<sup>1</sup> Vitamin D's physiologic contributions to health and the potentially detrimental effects of its deficiency are gradually being acknowledged as a major public health concern.<sup>2</sup>

### Vitamin D Physiology

Vitamin D, a fat-soluble vitamin, exists in different forms, the most important of which are vitamin D<sub>2</sub> (ergocalciferol), which is synthesized by plants and found in foods such as eggs and fortified milk, and vitamin D<sub>3</sub> (cholecalciferol), which is generated by human skin exposed to sunlight (ultraviolet B light), causing photolytic conversion of 7-dehydrocholesterol to cholecalciferol. Epidermal synthesis of vitamin D<sub>3</sub> is the primary source of vitamin D for humans. Cholecalciferol binds with vitamin D-binding protein and is hydroxylated to 25-hydroxyvitamin D (25[OH]D), its serum circulating form, in the liver. Renal tissues process bound 25(OH)D, producing calcitriol (1,25-dihydroxyvitamin D). Calcitriol is found in endothelial, endocrine, brain, immune, and colon tissues.<sup>3</sup> Calcitriol binds to vitamin D receptor (VDR) for some

**Table** Cut-points for vitamin D adequacy, inadequacy, and deficiency

Vitamin D status	nmol/L <sup>a</sup>	Institute of Medicine <sup>8</sup> ng/mL <sup>a</sup>	Endocrine Society <sup>9</sup> ng/mL
Adequate	≥50	≥20	≥30
Inadequate	30 to <50	12 to <20	21 to 29
Deficient	<30	<12	≤20

<sup>a</sup> 1 nmol/L = 0.4 ng/mL

effects, while local tissue activates unbound 25(OH)D to calcitriol to drive a wide array of additional effects.<sup>4</sup> Both VDR and the enzyme that converts vitamin D to its active form exist in all body organs,<sup>5,6</sup> including endothelium, vascular smooth muscle, endothelium, cardiomyocytes, macrophages, and beta-pancreatic cells, enabling vitamin D's widespread physiologic influences.

### Definition of VDD

The best indicator of vitamin D status is serum concentration of 25(OH)D,<sup>7</sup> measured in either nanomoles per liter (nmol/L) or nanograms per milliliter (ng/mL). There are no universally accepted definitions to distinguish vitamin D adequacy, inadequacy, or deficiency, as illustrated by the contrasting cut-points in the Table and by the wide variation of values employed in research studies.

### Prevalence

Vitamin D deficiency is the most common nutritional deficiency globally for adults and children.<sup>10</sup> The combined prevalence of vitamin

©2017 American Association of Critical-Care Nurses  
doi:<https://doi.org/10.4037/ccn2017860>

D insufficiency and VDD is estimated at 42% of US adults, 69% of Hispanic and 82% of African Americans, owing to differences in diet and skin pigmentation.<sup>11</sup> Worldwide, an estimated 1 billion people have VDD,<sup>12</sup> suggesting this problem represents a pandemic.<sup>13,14</sup> For Americans older than 65 years, VDD prevalence is 50%, and rises to 70% to 90% among those cognitively impaired.<sup>15</sup>

### Potentially Detrimental Effects of VDD

A substantial volume of emerging evidence underscores the health problems attributable to a lack of sufficient vitamin D. An overview of the adverse outcomes related to VDD follows.

#### Increased Complications for Kidney Transplant Patients

Patients with chronic kidney disease requiring kidney transplant frequently have VDD, owing to impaired renal function. In these patients, low calcidiol levels are associated with poor graft survival, type 2 diabetes mellitus, metabolic and cardiovascular disorders, and higher mortality. Vitamin D<sub>3</sub> supplementation has helped mitigate acute rejection episodes.<sup>16</sup>

#### Diminished Muscle Development, Increased Falls and Fractures

Vitamin D assists in regulating calcium flux in muscle cells and in regulating muscle cell differentiation and proliferation, suggesting its enhancement of muscle development and contraction. In laboratory models, global deletion of VDR causes muscle atrophy, supporting its role in motor function.<sup>17</sup> Separate meta-analyses<sup>18,19</sup> of randomized controlled trials confirm that vitamin D improves lower limb muscle strength and reduces falls and fractures, particularly for those older than 65 and those with VDD.<sup>18</sup>

#### Role of Vitamin D in Cardiovascular Health

Vitamin D appears to bestow protective effects on cardiovascular health that are diminished or lost with VDD, resulting in a higher prevalence of cardiovascular risk factors, morbidity, and mortality. Some of the mechanisms proposed to explain these outcomes include loss of vitamin D's protective vascular and endothelial effects through its influence on nitric oxide, the renin-angiotensin-aldosterone system, inflammatory cytokines, and mediators of thrombus formation.<sup>20</sup>

#### Higher CVD Morbidity and Mortality

Longitudinal study meta-analysis reveals a strong, virtually linear, inverse association between vitamin D concentration and CVD risk (total CVD, CVD mortality, coronary heart disease, stroke). In general, the lower the vitamin D, the higher the CVD risk.<sup>21</sup> Similar results were reported for type 2 diabetes, where the association of VDD is considered a prognostic factor for cardiovascular morbidity and mortality.<sup>22</sup> There is also abundant evidence of an inverse relationship between serum vitamin D and many of the risk factors for CVD. This link may be at least partly explained by VDR presence in the myocardium and vascular tissues.<sup>23-25</sup>

#### Increased Prevalence of CVD Risk Factors

Numerous studies demonstrate that VDD contributes to development of hypertension,<sup>26,27</sup> diabetes,<sup>28-30</sup> obesity,<sup>31</sup> and metabolic syndrome.<sup>32</sup> Low vitamin D is inversely correlated with elevated systolic blood pressure (SBP),<sup>33</sup> type 2 diabetes,<sup>34</sup> and obesity.<sup>31</sup> SBP can even be predicted using the vitamin D level.<sup>33</sup> The high prevalence of VDD in obesity is attributed to dilution or sequestration of vitamin D in adipose tissue.<sup>31</sup>

#### Higher Prevalence of Metabolic Syndrome

Metabolic syndrome (MS) identifies persons at heightened risk for CVD owing to their combination of risk factors: obesity, hypertension, elevated triglycerides, hyperglycemia (insulin resistance), and reduced high-density lipoprotein cholesterol.<sup>35</sup> A recent study found a high prevalence of VDD associated with MS: 60% of MS patients had VDD, 27% vitamin D insufficiency.<sup>33</sup> This same study confirmed that vitamin D is inversely correlated with SBP, total cholesterol, low-density lipoprotein cholesterol, triglycerides, and glycemic control (HbA1c) and directly correlated with pancreatic  $\beta$  cell function.<sup>33</sup> Unfortunately, a meta-analysis of 51 vitamin D supplementation studies failed to improve lipids, SBP, stroke, or myocardial infarction.<sup>36</sup>

#### Greater Incidence, Morbidity and Mortality for Acute Myocardial Infarction

Several important associations exist between VDD and acute myocardial infarction (AMI): VDD is highly prevalent in AMI<sup>37-43</sup>; risk of AMI is significantly higher and inversely proportional to the degree of VDD<sup>37</sup>; and AMI patients with VDD fare significantly worse with

greater morbidity, postinfarction complications, and higher mortality.<sup>39-41,43</sup> One study found rates of major cardiovascular events were 50% higher with vitamin D insufficiency and 80% higher with VDD.<sup>44</sup> At a 10-year follow-up of more than 18000 men, those with low vitamin D levels had twice the risk of AMI as those with adequate vitamin D.<sup>45</sup> A larger meta-analysis confirmed that VDD constitutes a unique risk factor for AMI and CVD.<sup>46</sup> Longer-term outcomes support that finding, with the lowest vitamin D levels linked to greater rehospitalizations for acute heart failure (HF) and subsequent acute coronary syndrome,<sup>40</sup> higher 1-year mortality,<sup>39</sup> and deaths from HF and sudden cardiac death.<sup>47</sup>

### Reduced Exercise Capacity and Higher Mortality in HF

One of the definitive manifestations of HF, often considered a prognostic marker, is diminished exercise capacity, measured via peak oxygen consumption ( $\dot{V}O_2$ ). A recent study found that 87% of HF patients had VDD (<20 ng/mL) and 25% had severe VDD (<10 ng/mL); those with severe VDD had significantly lower  $\dot{V}O_2$ , peak  $\dot{V}O_2$ %, and higher brain natriuretic peptide compared with those with higher levels.<sup>48</sup> These findings support other reports<sup>49</sup> that low vitamin D is associated with muscular impairment and poor prognosis in HF with limited improvement from cardiovascular rehabilitation.<sup>50</sup>

### Increased Risk and Poor Outcomes for Ischemic Stroke

A recent study discerned that VDD correlates with increased inflammatory markers, risk of ischemic stroke, and poor short-term outcomes.<sup>51</sup> Patients with ischemic stroke had lower levels of vitamin D, higher prevalence of VDD, and higher high-sensitivity C-reactive protein than controls. Three months later, stroke patients with poor outcomes had lower VDD levels than those with good outcomes, suggesting that vitamin D has an important role in the inflammatory response, pathophysiology, and recovery from acute ischemic stroke.<sup>51</sup>

### Increased Immune Dysfunction: Inflammation, Infection, and Sepsis

The role of vitamin D in regulation of the innate and adaptive immune systems has been recognized for some time.<sup>52</sup> The mechanisms responsible are believed to include direct expression of antimicrobial peptides,

stimulated production of suppressive T cells, and suppression of proinflammatory T<sub>H</sub>17 cells.<sup>53</sup> VDD <50 nmol/L represents a serious risk factor for infection, sepsis, and mortality in critically ill patients, as it increases susceptibility for severe infections and mortality.<sup>54</sup> This link between VDD and inflammatory biomarkers is also found in patients with multiple sclerosis, rheumatoid arthritis, and advanced age.<sup>55</sup>

An interesting link among vitamin D, immunity, insulin resistance, and CVD was revealed in laboratory mice when researchers genetically eliminated macrophage VDRs and the mice developed arterial atherosclerotic plaques and insulin resistance due to hepatic and vascular inflammation. Eliminating monocyte VDR led to monocyte adherence to vascular walls, cholesterol deposition, and release of inflammatory mediators that caused diabetes and heart disease. When bone marrow transplants restored VDRs to macrophages and monocytes, the laudatory benefits of vitamin D appeared: atherosclerosis suppression, insulin sensitivity, and lack of macrophage accumulation.<sup>56</sup>

### More Severe Traumatic Brain Injury and Lower Quality of Life

In a study of the relationship between vitamin D levels and severity of head injury, patients with severe traumatic brain injury (TBI) had significantly lower vitamin D levels than those with mild TBI. In addition, self-reported quality of life was better for patients with optimum vitamin D compared with those with VDD, even after controlling for injury severity. The authors recommend active screening of TBI patients to identify when VDD occurs and to prevent its detrimental effects on healing, morbidity, and CVD.<sup>57</sup>

### Increased and Accelerated Cognitive Decline

Low vitamin D levels are strongly associated with diminished cognitive performance and future cognitive decline, especially among the elderly.<sup>58</sup> In a large, ethnically diverse, longitudinal study, VDD (<12 ng/mL, 26%) and insufficiency (12 to <20 ng/mL, 35%) were prevalent among participants (mean age, 76 years) at the outset. Over 5 years, the cognitive performance of those with vitamin D levels less than 20 ng/mL declined at a rate 3 times faster than for those with adequate vitamin D levels (20-49 ng/mL). These substantial cognitive losses, especially in episodic and semantic memory and

executive function (problem-solving, following directions, reasoning) related to dementia and Alzheimer disease, were independent of baseline cognitive ability, race, ethnicity, or other risk factors.<sup>59</sup>

Some of the neurosteroid actions of vitamin D that may account for its notable effects on cognition include clearance of amyloid- $\beta$  peptide and antioxidant, anti-inflammatory effects that may protect against the neurodegeneration associated with Alzheimer disease. Some researchers consider supplemental vitamin D as crucial to slow, prevent, or improve neurocognitive decline.<sup>60</sup> Comparable findings were reported in China, where individuals with lower baseline vitamin D were 2 to 3 times more likely to have significant cognitive decline within 2 years compared to those with adequate levels.<sup>61</sup>

### Loss of Antineoplastic Protection

There is some evidence that low vitamin D concentrations may be associated with greater risk of colorectal cancer,<sup>62</sup> though vitamin D supplementation has not demonstrated any benefit for prevention.<sup>63</sup> Although it may not reduce the incidence of cancer, there is evidence that vitamin D may lower its mortality.<sup>64</sup>

### Increased Risk of All-Cause Mortality

The protective functions afforded by vitamin D can be perceived as culminating in perhaps its most important attribute: its capacity to reduce mortality. In addition to single reports suggesting that higher vitamin D levels confer mortality benefits,<sup>39-41,43,47,66,67</sup> a number of randomized controlled trial meta-analyses demonstrate the consistency of the inverse relationship between vitamin D level and mortality from any cause.<sup>68-72</sup>

### Closing

The detrimental physiologic effects of VDD are widespread and can wreak multisystem morbidity before inflicting lethality. Assessing, monitoring, and optimizing serum vitamin D may be a lifesaving intervention that we can no longer overlook. **CCN**



JoAnn Grif Alsapach, RN, MSN, EdD  
Editor

### References

1. Christakos S, Hewison M, Gardner DG, et al. Vitamin D: beyond bone. *Ann N Y Acad Sci*. 2013;1287:45-58.
2. Wilson LR, Tripkovic L, Hart KH, Lanham-New SA. Vitamin D deficiency as a public health issue: using vitamin D2 or vitamin D3 in future fortification strategies. *Proc Nutr Soc*. 2017;28:1-8.
3. Henry HL. Regulation of vitamin D metabolism. *Best Pract Res Clin Endocrinol Metab*. 2011;25:531-541.
4. Hassan-Smith ZK, Hewison M, Gittoes NJ. Effect of vitamin D deficiency in developed countries. *Br Med Bull*. 2017;9:1-11.
5. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. *J Chem Neuroanat*. 2005;29(1):21-30.
6. Eyles DW, Liu PY, Josh P, Cui X. Intracellular distribution of the vitamin D receptor in the brain: comparison with classic target tissues and redistribution with development. *Neuroscience*. 2014;268:1-9.
7. National Institutes of Health, Office of Dietary Supplements, Vitamin D Fact Sheet for Health Professionals. <https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/>. Last updated: February 11, 2016. Accessed April 10, 2017.
8. Institute of Medicine, Food and Nutrition Board. *Dietary Reference Intakes for Calcium and Vitamin D*. Washington, DC: National Academy Press; 2010.
9. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96:1911-1930.
10. Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. *Mayo Clin Proc*. 2013;88:720-755.
11. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. *Nutr Res*. 2011;31(1):48-54.
12. Holick M. Vitamin D deficiency. *N Engl J Med*. 2007;357:266-281.
13. Cashman KD, Dowling KG, Skrabáková Z, et al. Vitamin D deficiency in Europe: pandemic? *Am J Clin Nutr*. 2016;103:1033-1044.
14. Absoud M, Cummins C, Lim MJ, et al. Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study. *PLoS One*. 2011;6:e22179.
15. Annweiler C, Dursun E, Feron F, et al. "Vitamin D and cognition in older adults": updated international recommendations. *J Intern Med*. 2015;277(1):45-57.
16. Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. *Nutrients*. 2017;9(4). pii:E328.
17. Girgis CM, Clifton-Bligh RJ, Hamrick MW, et al. The roles of vitamin D in skeletal muscle: form, function, and metabolism. *Endocr Rev*. 2013;34:33-83.
18. Murad MH, Elamin KB, Abu Elnour NO, et al. Clinical review: the effect of vitamin D on falls: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2011;96:2997-3006.
19. Beaudart C, Buckinx F, Rabenda V, et al. The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab*. 2014;99:jc20141742.
20. Pérez-Hernández N, Aptilon-Duque G, Nostroza-Hernández MC, et al. Vitamin D and its effects on cardiovascular diseases: a comprehensive review. *Korean J Intern Med*. 2016;31:1018-1029.
21. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. *Circ Cardiovasc Qual Outcomes*. 2012;5:819-829.
22. Samefors M, Scragg R, Länne T, Nyström FH, Östgren CJ. Association between serum 25(OH)D3 and cardiovascular morbidity and mortality in people with type 2 diabetes: a community-based cohort study. *Diabet Med*. 2017;34(3):372-379.
23. Sonjén D, Weisman Y, Kohen F, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. *Circulation*. 2005;111:1666-1671.
24. Yao T, Ying X, Zhao Y, et al. Vitamin D receptor activation protects against myocardial reperfusion injury through inhibition of apoptosis and modulation of autophagy. *Antioxid Redox Signal*. 2015;22:633-650.
25. Kawashima H. Receptor for 1,25-dihydroxyvitamin D in a vascular smooth muscle cell line derived from rat aorta. *Biochem Biophys Res Commun*. 1987;146:1-6.
26. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. *Hypertension*. 2007;49:1063-1069.
27. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. *Hypertension*. 2008;52:828-832.
28. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. *Diabetes Care*. 2004;27:2813-2818.



29. Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. *Kidney Int.* 2007;71:134-139.
30. Mattila C, Knekt P, Männistö S, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. *Diabetes Care.* 2007; 30:2569-2570.
31. Pannu PK, Zhao Y, Soares MJ. Reductions in body weight and percent fat mass increase the vitamin D status of obese subjects: a systematic review and metaregression analysis. *Nutr Res.* 2016;36:201-213.
32. Hyppönen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. *Diabetes.* 2008;57:298-305.
33. Alkhatatbeh MJ, Abdul-Razzak KK, Khasawneh LQ, Saadeh NA. High prevalence of vitamin D deficiency and correlation of serum vitamin D with cardiovascular risk in patients with metabolic syndrome [published online ahead of print March 27, 2017]. *Metab Syndr Relat Disord.* doi:10.1089/met.2017.0003.
34. Song Y, Wang L, Pittas AG, et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. *Diabetes Care.* 2013;36:1422-1428.
35. Grundy SM, Cleeman Jr, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. *Circulation.* 2005; 112:2735-2752.
36. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2011;96:1931-1942.
37. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. *Int J Epidemiol.* 1990;19:559-563.
38. Lund B, Badskaer J, Lund B, Soerensen OH. Vitamin D and ischaemic heart disease. *Horm Metab Res.* 1978;10:553-556.
39. De Metrio M, Milazzo V, Rubino M, et al. Vitamin D plasma levels and in-hospital and 1-year outcomes in acute coronary syndromes: a prospective study. *Medicine (Baltimore).* 2015;94:e857.
40. Ng LL, Sandhu JK, Squire IB, Davies JE, Jones DJ. Vitamin D and prognosis in acute myocardial infarction. *Int J Cardiol.* 2013;168:2341-2346.
41. Aleksova A, Belfiore R, Carriere C, et al. Vitamin D deficiency in patients with acute myocardial infarction: an Italian single-center study. *Int J Vitam Nutr Res.* 2015;85:23-30.
42. Lee JH, Gadi R, Spertus JA, Tang F, O'Keefe JH. Prevalence of vitamin D deficiency in patients with acute myocardial infarction. *Am J Cardiol.* 2011;107:1636-1638.
43. Correia LC, Sodr e F, Garcia G, et al. Relation of severe deficiency of vitamin D to cardiovascular mortality during acute coronary syndromes. *Am J Cardiol.* 2013;111:324-327.
44. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. *Circulation.* 2008;117:503-511.
45. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. *Arch Intern Med.* 2008;168:1174-1180.
46. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. *Circ Cardiovasc Qual Outcomes.* 2012;5:819-829.
47. Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients. *Inflamm Allergy Drug Targets.* 2013;12:273-281.
48. Saponaro F, Marcocci C, Zucchi R, et al. Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients' survival [published online ahead of print March 23, 2017]. *Endocrine.* doi:10.1007/s12020-017-1282-9.
49. Kaul A, Gl aser S, Hannemann A, et al. Vitamin D is associated with cardiopulmonary exercise capacity: results of two independent cohorts of healthy adults. *Br J Nutr.* 2015;25:1-9.
50. Ucay O, Pouche M, Guiraud T, Besnier F, Pathak A, Labrunee M. Vitamin D deficiency related to physical capacity during cardiac rehabilitation. *Ann Phys Rehabil Med.* 2017;60(1):2-5.
51. Alfieri DF, Lehmann MF, Oliveira SR, et al. Vitamin D deficiency is associated with acute ischemic stroke, C-reactive protein, and short-term outcome. *Metab Brain Dis.* 2017;32(2):493-502.
52. Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. *Mol Cell Endocrinol.* 2004;215(1-2):31-38.
53. Chun RF, Adams JS, Hewison M. Immunomodulation by vitamin D: implications for TB. *Expert Rev Clin Pharmacol.* 2011;4:583-591.
54. De Haan K, Groeneveld AJ, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. *Critical Care.* 2014; 18(6):660.
55. Laird E, McNulty H, Ward M, et al. Vitamin D deficiency is associated with inflammation in older Irish adults. *J Clin Endocrinol Metabol.* 2014;99(5):1807.
56. Oh J, Riek AE, Darwech I, et al. Deletion of macrophage vitamin D receptor promotes insulin resistance and monocyte cholesterol transport to accelerate atherosclerosis in mice. *Cell Rep.* 2015;10(11):1872-1886.
57. Toman E, Bishop JR, Davies DJ, et al. Vitamin D deficiency in traumatic brain injury and its relationship with severity of injury and quality of life: a prospective, observational study. *J Neurotrauma.* 2017;34(7):1448-1456.
58. Wilson VK, Houston DK, Kilpatrick L, et al. Relationship between 25-hydroxyvitamin D and cognitive function in older adults: the Health, Aging and Body Composition Study. *J Am Geriatr Soc.* 2014;62(4):636.
59. Miller JW, Harvey DJ, Beckett LA, et al. Vitamin D status and rates of cognitive decline in a multiethnic cohort of older adults. *JAMA Neurology.* 2015;72(11):1295-1303.
60. Annweiler C. Vitamin D in dementia prevention. *Ann NY Acad Sci.* 2016;1367:57-63.
61. Matchar DB, Chei CL, Yin Z-X, et al. Vitamin D Levels and the Risk of Cognitive Decline in Chinese Elderly People: the Chinese Longitudinal Healthy Longevity Survey. *J Gerontol A Biol Sci Med Sci.* 2016;71(10):1363-1368.
62. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. *Int J Cancer.* 2011;128:1414-1424.
63. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of cancer in adults. *Cochrane Database Syst Rev.* 2014; 6:1465-1858.
64. Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. *Br J Cancer.* 2014;111:976-980.
65. Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients. *Inflamm Allergy Drug Targets.* 2013;12:273-281.
66. Braun AB, Litonjua AA, Moromizato T, Gibbons FK, Giovannucci E, Christopher KB. Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill. *Crit Care Med.* 2012;40: 3170-3179.
67. Moromizato T, Litonjua AA, Braun AB, Gibbons FK, Giovannucci E, Christopher KB. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill. *Crit Care Med.* 2014;42:97-107.
68. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. *Arch Intern Med.* 2007; 167:1730-1737.
69. De Haan K, Groeneveld AJ, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. *Critical Care.* 2014;18(6): 660-668.
70. Sch ottker B, Jorde R, Peasey A, et al. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. *BMJ.* 2014;348:g3656. doi:10.1136/bmj.g3656.
71. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomized intervention studies. *BMJ.* 2014;348:g1903.
72. Gaksch M, Jorde R, Grimnes G, et al. Vitamin D and mortality: individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium. *PLoS One.* 2017; 12(2):e0170791.